A
Arvinas D
D
ARVN
8.25500
USD
-0.01
(-0.12%)
Pre Open·8.15000USD-0.10500(-1.27%)
Volume
29,313
EPS
-4
Div Yield
-
P/E
-3
Market Cap
532,622,489
Title: Arvinas
Sector: Healthcare
Industry: Biotechnology
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to targetcertain harmful proteins causing oncology and neurology-related diseases.








